Omnicell (OMCL) Tops Q4 EPS by 3c, Revenues Miss; Offers Q1 & FY19 EPS Mid-Point Guidance Above Consensus, Q1 Revenues Guidance Below Consensus, FY19 Revenue Outlook Tops Views

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Omnicell (OMCL) Tops Q4 EPS by 3c, Revenues Miss; Offers Q1 & FY19 EPS Mid-Point Guidance Above Consensus, Q1 Revenues Guidance Below Consensus, FY19 Revenue Outlook Tops Views

Omnicell Reports Results for Fiscal Year and Fourth Quarter 2018

February 7, 2019 4:01 PM EST

MOUNTAIN VIEW, Calif., Feb. 7, 2019 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions to healthcare systems, today announced results for its fiscal year and fourth quarter ended December 31, 2018.

GAAP Results

GAAP revenues for the fourth quarter of 2018 were $211.8 million, up... More